Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.

Front Immunol · 2018 · PMC5827539 · PMID 29520266

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

18.8%; p = 0.549) did not differ significantly; however, it showed a clear trend of ineffectiveness of RTX in IgA-dominant cases.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.